Below you will find some of the most commonly asked questions about ZMapp®.

What is ZMapp®?

ZMapp® is an experimental new therapy that is being developed to treat patients with Ebola. It is comprised of a series of three different monoclonal antibodies that work to prevent the spread of the disease within the body.

Who developed ZMapp®?

The development of ZMapp® is a group effort – a great example of scientists working together to get the best results. It was a public-­‐private partnership comprised of a consortium of scientists from the Public Health Agency of Canada, Defyrus, the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), Kentucky BioProcessing, and Mapp Biopharmaceutical, among other institutions, who joined together to advance plant-­‐based antibody therapies to combat Ebola. Mapp Bio has been working on multiple plant-­‐based antibody therapies and preventatives since 2003.

How is ZMapp® administered?

ZMapp® is administered intravenously, i.e. it is introduced directly into a patient’s bloodstream.

What are the potential side effects?

ZMapp® is an experimental therapy that must be tested in clinical trials for safety (and efficacy). Other monoclonal antibody therapies, of which there are over 30 approved by the FDA, have a good safety record.